|Bid||12.70 x 800|
|Ask||12.71 x 800|
|Day's range||12.35 - 13.04|
|52-week range||4.52 - 19.36|
|Beta (5Y monthly)||2.22|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.00|
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial results after market close on Wednesday, August 5, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.